相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses
Grammatiki Fotaki et al.
ONCOIMMUNOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
Alex Karlsson-Parra et al.
PHARMACEUTICAL RESEARCH (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
Tomi Akinyemiju et al.
JAMA ONCOLOGY (2017)
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
Anna Laurell et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy
Suresh Gopi Kalathil et al.
JCI INSIGHT (2016)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Potentiality of immunotherapy against hepatocellular carcinoma
Nobuhiro Tsuchiya et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Complications associated with renal graft biopsy in transplant patients
Claudia Tapia-Canelas et al.
NEFROLOGIA (2014)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
Katherine A. McGlynn et al.
CLINICS IN LIVER DISEASE (2011)
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
Mengde Cao et al.
LABORATORY INVESTIGATION (2011)
Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
Andreas Draube et al.
PLOS ONE (2011)
Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metabolic Syndrome and Hepatocellular Carcinoma Two Growing Epidemics With a Potential Link
Abby B. Siegel et al.
CANCER (2009)
Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages
Dorothee Duluc et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
Karin Gustafsson et al.
CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming:: A functional link between direct and indirect allosensitization
AC Wallgren et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2005)
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas
G Mazzolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dendritic cells in transplantation - Friend or foe?
R Lechler et al.
IMMUNITY (2001)
分享论文
